Amphiregulin as a biomarker for monitoring lifethreatening acute graft-<i>versus</i>-host disease: secondary analysis of two prospective clinical trials
Shernan G. Holtan,
Najla El Jurdi,
Armin Rashidi,
Brian C. Betts,
Connor Demorest,
John P Galvin,
Margaret L. MacMillan,
Daniel J. Weisdorf,
Angela Panoskaltsis-Mortari,
Michael A. Pratta
Affiliations
Shernan G. Holtan
University of Minnesota, Adult Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN
Najla El Jurdi
University of Minnesota, Adult Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN
Armin Rashidi
University of Minnesota, Adult Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN; Fred Hutchinson Cancer Center
Brian C. Betts
University of Minnesota, Adult Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN
Connor Demorest
Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN
John P Galvin
Incyte Corporation, Wilmington, DE
Margaret L. MacMillan
University of Minnesota, Pediatric Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN
Daniel J. Weisdorf
University of Minnesota, Adult Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN
Angela Panoskaltsis-Mortari
University of Minnesota, Pediatric Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN
